Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Vertex Reports Interim Analysis Data From Phase 2 Study Of VX-809 And Kalydeco

Vertex Pharmaceuticals Inc. (VRTX: Quote) announced an interim analysis of data from an ongoing Phase 2 study of VX-809 and Kalydeco (ivacaftor) that showed significant improvements in lung function or FEV1 among adults with cystic fibrosis or CF who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator or CFTR gene, F508del.

A planned interim analysis was conducted after approximately half of the study patients had completed 56 days of treatment.

The company said that today's results are based on data from 37 homozygous F508del patients who completed treatment in the 56-day study and 11 patients with one or two copies of the F508del mutation who received placebo.

According to interim analysis of data, there was a statistically significant improvement in lung function (absolute change in percent predicted FEV1) across the combined treatment groups relative to baseline compared to placebo (p=0.002). Of those who received VX-809 and Kalydeco (250mg, q12h), approximately 46 percent (17/37) experienced an absolute improvement from baseline to Day 56 in lung function of 5 percentage points or more, and approximately 30 percent (11/37) experienced an absolute improvement from baseline to Day 56 of 10 percentage points or more.

The company stated that none of the patients treated with placebo (0/11) achieved a 5-percentage point or more improvement from baseline to Day 56 in lung function. Most adverse events were mild or moderate in severity and comparable between treatment and placebo groups.

The study is ongoing and complete data, including statistical analyses for all patient groups, will be available in mid-2012.

Vertex noted that it plans to start a pivotal study of VX-809 and Kalydeco in people with two copies of the F508del mutation, pending final study results and discussions with regulatory agencies.

Register
To receive FREE breaking news email alerts for Vertex Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
German unemployment reached the lowest in more than two decades in November, boosting confidence among businesses and households. The seasonally adjusted jobless rate for November was 6.6 percent, unchanged from October's figure that was downwardly revised, data from the Federal Labor Agency showed Thursday. Eurozone money supply supply growth remained steady in October, while lending to the private sector continued to fall, despite the stimulus efforts from the European Central Bank. The annual growth of broad money, or M3, was 2.5 percent in October, unchanged from September, the ECB said on Thursday.... Australia's international cricketer Phillip Hughes, who sustained critical injury after being hit on the head by a ball during a domestic match Tuesday, has died. The 25 year-old promising player had been fighting for his life for two days at St Vincent's Hospital in Sydney, in induced coma. Australian cricket team's doctor Peter Brukner said at a news conference Thursday that Hughes died as a
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.